When burning mouth syndrome occurs in the context of xerostomia, the co-existing oral dryness shapes the clinical approach. This protocol targets that specific scenario with a focused first-line intervention strategy.
Patients present with burning mouth syndrome alongside xerostomia (dry mouth). The xerostomic component defines the therapeutic direction and distinguishes this sub-population from other BMS presentations.
Management centres on topical agents directed at the xerostomic component — specifically, anti-xerostomic saliva-replacement formulations applied locally. The full options, sequencing, and application details are available in the structured protocol.
The primary clinical target is reduction in oral burning pain, measured by VAS (visual analogue scale) score.
DOI: 10.1177/03331024211036152
Lysozyme lactoperoxidase (Biotene) rinse was prescribed to BMS patients diagnosed with xerostomia and reported a decrease in pain score of 1.7 units during short-term assessment (SMD 0.93, 95% CI 1.72 to 0.13) but no advantage over placebo was seen in long-term assessment (SMD 0.73, 95% CI 1.72 to 0.26).
Statistical analysis showed no statistically significant difference between the application of 10% urea for 3 months and the placebo group (p ¼ 0.34) (RR 0.95, 95% CI 0.50–1.80).
View source ↗